Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Switch Versus Standard Intravenous Antibiotics in Children and Adolescents Who Are Immunocompromised and/or a Central Venous Catheter and Uncomplicated Bloodstream Infections: a Nationwide Randomised Controlled Non-inferiority Trial

NCT07923266 is registered in ClinicalTrials.gov with Copenhagen University Hospital, Rigshospitalet as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07923266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Switch Versus Standard Intravenous Antibiotics in Children and Adolescents Who Are Immunocompromised and/or a Central Venous Catheter and Uncomplicated Bloodstream Infections: a Nationwide Randomised Controlled Non-inferiority Trial
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Phase
Phase 4
Overall status
Recruiting
Start date
November 9, 2026
Completion date
February 1, 2030
Enrollment
114 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bacteremia sepsis, bloodstream infection, bloodstream infection due to central venous catheter, immunocompromised patients

Arms

As registered; 2 arms.

  • Early Oral Switch ExperimentalOral antibiotic therapy

    Early Oral Switch

  • Standard Intravenous Therapy Active comparatorStandard IV antibiotic therapy

    Standard Intravenous Therapy

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Recurrence of blood stream infection Within 6 weeks after randomization

    Number of patients who experience growth of the same bacteria as in the index blood stream infection in a subsequent blood culture during the follow-up period.

Lead sponsor's other trials

Copenhagen University Hospital, Rigshospitalet, most recent start first.

Similar trials

Same condition (Bacteremia) and phase, most recent start first.